 BetterLife Pharma Inc CSE:BETR OTCQB:BETRF FRA:NPAU has said it is partnering up with Carleton University in Ottawa to study TD-0148A - a second-generation LSD molecule - to treat depression. BetterLife reckons the therapy will mimic the projected therapeutic potential of LSD without causing undesirable psychoactive dissociative side effects. 